Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT05672199
- Locations
- 🇺🇸
Santa Maria Gastroenterology Medical Group, Santa Maria, California, United States
🇺🇸Indian Health Service Health Research, Kissimmee, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes MellitusOverweightObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 592
- Registration Number
- NCT05669599
- Locations
- 🇺🇸
Progressive Medical Research, Port Orange, Florida, United States
🇺🇸Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸Research Innovations LLC dba Internal Medicine Care Inc, Beavercreek, Ohio, United States
A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
- Conditions
- Idiopathic Inflammatory Myositis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT05669014
- Locations
- 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇧🇷Centro Mineiro de Pesquisa - CMiP, Juiz De Fora, Minas Gerais, Brazil
🇧🇷LMK Servicos Medicos SS, Porto Alegre, Rio Grande Do Sul, Brazil
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 726
- Registration Number
- NCT05651711
- Locations
- 🇺🇸
Wendy Sadoff MD Dermatology PC, Farmington Hills, Michigan, United States
🇺🇸Crystal Run Healthcare, Monroe, New York, United States
🇺🇸Epic Clinical Research Incorporated, Lewisville, Texas, United States
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 187
- Registration Number
- NCT05633355
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸ARA Professionals Limited Liability Corporation, Miami, Florida, United States
🇺🇸Dermatology Trial Associates, Bryant, Arkansas, United States
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
- Conditions
- Diffuse Cutaneous Systemic SclerosisSclerosis, Systemic
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 174
- Registration Number
- NCT05626751
- Locations
- 🇰🇷
Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Arizona Arthritis and Rheumatology Associates -4550 E Bell Rd, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05599828
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05598281
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
- Conditions
- Discoid Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 99
- Registration Number
- NCT05591222
- Locations
- 🇺🇸
Wallace Medical Group, Beverly Hills, California, United States
🇺🇸Arkansas Research Trials, North Little Rock, Arkansas, United States
🇺🇸The Center for Dermatology Clinical Research, Fremont, California, United States
A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05581758
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States